PLUR pluri-biotech.com Earnings growth forecast for next year
Pluri Inc. is scaling 3D cell technologies for medicine and eco-meat. The projected earnings per share growth for the next fiscal year reflects expectation dynamics, where the value of 0.00 expresses the metric level. Competent Israeli management effectively secures grants and protects patents, while the company strictly adheres to bio-waste disposal regulations to minimize its operational footprint.
PLUR (Pluri): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- market capitalization data:
- book capitalization indicators:
- debt and solvency information:
Total Debt to Capital Pluri Inc.|PLUR - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Pluristem Therapeutics|PLUR - Company Total Debt Obligations|Debt to Book Capitalization Ratio Pluri|PLUR - Company Long-Term Liabilities|Company Short-Term Debt Pluri|Quick Liquidity pluri-biotech.com
- net income and valuation ratios data:
PLUR - Company Net Income|Future Profit Pluri Inc.|PLUR - P/E Multiple|Future Price to Earnings Pluristem Therapeutics|PLUR - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Pluri|PLUR - Operating income before deduction of amortization|Net earnings per share for the last 12 months Pluri|PLUR - Earnings per share for the trailing year|Quarterly EPS earnings growth pluri-biotech.com|PLUR - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Pluri Inc.
- total revenue and sales volume data:
Initial company analysis:PLUR, Pluri Inc.
To assess long-term risks, an investor analyzes the consensus earnings forecast for the coming year, which reflects analysts' average expectations for net income growth rates. The trend in the projected EPS growth rate for next year helps identify deviations from a sustainable yield corridor. For Pluri Inc. (PLUR), such stability is confirmed by the isolation of the biotech cycle from macroeconomic shocks, transforming the asset into a defensive tool.
Analysis of competing companies
ASND (Ascendis Pharma Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year Madrigal Corp|Earnings growth forecast for next year CORT|Net earnings per share growth forecast for next year RYTM (rhythmtx.com)|Net earnings per share growth forecast for next year Akero AKRO|Metsera, Inc. (MTSR) - Expected net earnings per share growth next year|MLTX - Net earnings per share growth forecast for next year|CRNX: Net earnings per share growth forecast for next year|NAMS: Earnings growth forecast for next year|SLNO - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Amicus Therapeutics, Inc.|89bio Inc (ETNB) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Agios Pharmaceuticals Inc (AGIO)|Expected earnings per share growth for next year Structure Corp GPCR|Net earnings per share growth forecast for next year MiMedx Group, Inc. MDXG|RZLT (rezolutebio.com) - Net earnings per share change forecast for next year|LXRX - Net earnings per share growth forecast for next year|MBX: Net earnings per share growth forecast for next year|ALT (Altimmune Corp) - Expected earnings per share growth for next year|Aardvark Pharma (AARD) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Sagimet Biosciences|BIOA: Expected earnings per share trend next year|Earnings growth forecast for next year BMEA|Consensus forecast of earnings per share growth for next year quincetx.com|Fractyl - Expected earnings per share growth for next year|Expected earnings per share trend next year VTVT|Agape ATP Corp. - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Synlogic, Inc. SYBX|Lipocine (LPCN) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year MTNB|SPRB (Spruce Biosciences, Inc.) - Earnings growth forecast for next year|Expected earnings per share growth for next year Galecto Corporation (GLTO)|Expected earnings per share growth for next year CTCX (Carmell Corporation)|Consensus forecast of earnings per share growth for next year lumos-pharma.com|Net earnings per share growth forecast for next year Organovo ONVO|RDUS (Radius Recycling Inc.) - Net earnings per share change forecast for next year
